Previous 10 | Next 10 |
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates - Company is advancing its integrin program and on schedule for initiating clinical studies in 2023 - Expanding immuno-oncology pipeline through strategic transac...
NEW YORK and LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LBT4) systems...
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 / JTC Team ("JTC"), a fully integrate...
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer - Dr. Brake formerly held leadership roles at Takeda Oncology, including Vice President, Global Project Leader in the Oncology Therapeutic Area and Head, U.S. Medical Affairs, Oncology Business Uni...
Last week was mixed for the penny stocks and higher-priced ones alike. While there were plenty of trends to follow, some continued gaining steam heading into the middle of November. Sure, you’ve got things like metaverse stocks, short squeeze penny stocks , and your typical low f...
Corbus Pharmaceuticals (NASDAQ:CRBP): Q3 GAAP EPS of -$0.02 beats by $0.10. Revenue of $0.1M (-91.9% Y/Y) misses by $0.43M. Press Release As of September 30, 2021, the company has $108M of cash and investments on hand which is expected to fund operations into the first quarter of 2024, based ...
Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates - Company continues to advance integrin program from preclinical development toward the clinic - Expanding pipeline through strategic transactions remains key priority - Ca...
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference - Fireside chat webcast will be available beginning on Thursday, November 18th at 8:00 AM GMT (3:00 AM ET) PR Newswire NORWOOD, Mass. , Nov. 11, 2021 /PRNewswire/ -- Corbus Pharma...
LEXINGTON, Mass. and AMSTERDAM, Oct. 21, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Rachelle Jacques to its Board of Directors. Ms. Jac...
Corbus Pharmaceuticals (NASDAQ:CRBP): Q2 GAAP EPS of -$0.15 misses by $0.03. Revenue of $0.14M (-53.3% Y/Y) misses by $0.57M. Shares -1.5% PM. Press Release Cash and investments on hand of $114M provides projected runway into first quarter of 2024 For further details see: Corbus Pharmac...
News, Short Squeeze, Breakout and More Instantly...
Corbus Pharmaceuticals Holdings Inc. Company Name:
CRBP Stock Symbol:
NASDAQ Market:
NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor me...
Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024 $116M of capital raised in Q1 2024 extending cash runway through Q1 2027 Appointed Dr. Dominic Smethurst as Chief Medical Officer NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIR...
NORWOOD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announce...